These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1360528)

  • 1. Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers.
    Fujimaki Y; Sudo K; Hakusui H; Tachizawa H; Murasaki M
    J Pharm Pharmacol; 1992 Sep; 44(9):750-4. PubMed ID: 1360528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring.
    Fujimaki Y; Sudo K; Hakusui H
    Xenobiotica; 1993 Jan; 23(1):61-70. PubMed ID: 8484264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single dose toxicity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs.
    Sugawara T; Kato M; Furuhama K; Inage F; Suzuki N; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):211-3. PubMed ID: 8018091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of impaired brain monoamine metabolism by the cognition-enhancing agent nefiracetam after microsphere-induced cerebral embolism in rats.
    Watabe S; Taniguchi K; Kojima H
    Arzneimittelforschung; 1994 Feb; 44(2A):195-8. PubMed ID: 7517140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug dependence study of the new cognition-enhancing agent nefiracetam in rats.
    Fujikawa K; Akiyama Y; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):243-7. PubMed ID: 8018097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits.
    Watanabe T; Matsuhashi K; Shimada M; Harada S; Tawara K; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):239-42. PubMed ID: 8018096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers.
    Tian Y; Zhang JJ; Feng SD; Zhang ZJ; Chen Y
    Arzneimittelforschung; 2008; 58(10):497-500. PubMed ID: 19025058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nefiracetam (DM-9384), a pyrrolidone derivative, on brain monoamine systems.
    Luthman J; Lindqvist E; Kojima H; Shiotani T; Tanaka M; Tachizawa H; Olson L
    Arch Int Pharmacodyn Ther; 1994; 328(2):125-44. PubMed ID: 7535993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats.
    Lal J; Gupta RC
    Arzneimittelforschung; 2008; 58(2):62-70. PubMed ID: 18412019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904), in man after single oral administration.
    Tanaka M; Ono K; Takegoshi T; Shiozawa T; Suzuki T; Nii S; Shibata H
    J Pharm Pharmacol; 1989 Oct; 41(10):680-4. PubMed ID: 2575144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.
    Nakashima M; Uematsu T; Kosuge K; Umemura K; Hakusui H; Tanaka M
    Antimicrob Agents Chemother; 1995 Jan; 39(1):170-4. PubMed ID: 7695301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenicity studies of the cognition-enhancing agent nefiracetam in mice and rats.
    Kajimura T; Satoh H; Rajasekaran D; Spicer EJ; Nakashima N; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):254-9. PubMed ID: 8018100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenicity study of the new cognition-enhancing agent nefiracetam.
    Shimada H; Hattori C; Tanaka N; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):251-3. PubMed ID: 8018099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenicity study of the new cognition-enhancing agent nefiracetam.
    Wagai N; Yamaguchi F; Hasegawa T; Takayama S
    Arzneimittelforschung; 1994 Feb; 44(2A):247-50. PubMed ID: 8018098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells.
    Yoshii M; Watabe S
    Brain Res; 1994 Apr; 642(1-2):123-31. PubMed ID: 8032872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.